NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc.
NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc.
Largest peer-reviewed study of nonendoscopic esophageal precancer testing to date demonstrates the efficiency and scalability of EsoCheck® cell collection in under two minutes NEW YORK, Nov. 3, 2026 /PRNewswire/ --
Conference Call and Webcast at 8:30 AM ETNEW YORK, Oct. 30, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company,
Conference Call and Webcast at 8:30 AM ETNEW YORK, Oct. 29, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics
Lucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rateSeries C Preferred Stock private placement with existing long-term shareholders
Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee ScheduleAMA CPT Editorial Panel approves a new Category III CPT code for non-endoscopic cell
Veris Health accelerated its commercial engagement with OSU-The JamesVeris Health implantable physiological monitor achieved development milestones towards upcoming FDA submissionLucid Diagnostics secured first
Recognized 2Q26 revenue of $1.5 millionProcessed 2,770 EsoGuard ® testsSecured first laboratory benefit manager (LBM) EsoGuard coverage policyConference call and webcast to be held today, August 13, at 8:30 AM EDTNEW
Concert's policy recognizes EsoGuard ® as the only esophageal precancer test meeting its coverage criteriaNEW YORK, Aug. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc.
Conference Call and Webcast at 8:30 AM ETNEW YORK, July 31, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company,
Conference Call and Webcast at 8:30 AM ETNEW YORK, July 30, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics
Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submissionLucid Diagnostics continued building commercial momentum and strengthened its balance sheet
Processed 3,177 EsoGuard® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement milestonesConference
